Simple Summary Pain associated with cancer diagnoses is a serious concern and one of
the most common symptoms reported by cancer patients. The insufficient relief of cancer …

Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

When peripheral neuropathy occurs due to chemotherapy treatment, it is referred to as
chemotherapy-induced peripheral neuropathy (CIPN). Typically, symptoms are sensory …

Importance Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating adverse
effect of neurotoxic cancer treatments including taxanes and platinum agents. Limited …

Background: Most individuals affected by cancer who are treated with certain
chemotherapies suffer of CIPN. Therefore, there is a high patient and provider interest in …

Background Chemotherapy-induced peripheral neuropathy (CIPN) is regarded as one of the
most common dose-limiting adverse effects of several chemotherapeutic agents, such as …

Background Chemotherapy‐induced peripheral neuropathy (CIPN) is a significant and
difficult to manage side effect of neurotoxic chemotherapies. Several risk factors for CIPN …

Chemotherapy‐induced peripheral neurotoxicity (CIPN) is a major toxicity of cancer
treatment, leading to dose reduction and premature treatment cessation, potentially affecting …

Chemotherapy-induced neuropathic pain (CINP) is one of the most severe side effects of
anticancer agents, such as platinum-and taxanes-derived drugs (oxaliplatin, cisplatin …

(1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are
available on the long-term prevalence and consequences of chemotherapy-induced …